feedback

Course Directors

Philip A. Thompson, MB, MS
Philip A. Thompson, MB, MS

The University of Texas MD Anderson Cancer Center
Houston, Texas

William G. Wierda, MD, PhD
William G. Wierda, MD, PhD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Accredited by

Penn State College of Medicine

View Activity Materials

Activity Description and Educational Objectives

In this activity, an expert panel of hematologist-oncologists offers guidance on best practices for integrating Bruton’s tyrosine kinase (BTK) inhibitor options into chronic lymphocytic leukemia (CLL) treatment by presenting real-world clinical scenarios designed to illustrate cutting-edge treatment selection and sequencing strategies across the spectrum of CLL care, from treatment-naïve to relapsed disease.

Upon completion of this activity, participants should be better able to:
  • Discuss the implications of mechanistic and selectivity differences among first- and second-generation BTK inhibitors in the context of CLL care
  • Summarize updated clinical evidence and practice guideline recommendations for the use of BTK inhibitors in treatment-naïve and relapsed CLL
  • Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, or in patients unable to tolerate BTK inhibitor therapy
  • Develop a management plan to address unique adverse events associated with the use of BTK inhibitors in patients with CLL

Target Audience

This activity has been designed to meet the educational needs of educational needs of hematologist-oncologists and other clinicians involved in the management of CLL.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: September 30, 2020 - September 29, 2021
Time to Complete: 75 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Co-Chairs
Philip A. Thompson, MB, MS
Assistant Professor, Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Philip A. Thompson, MB, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Genentech, Inc.; Gilead Sciences, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie; Genentech, Inc.; and Pharmacyclics LLC.
Other Financial or Material Support Janssen Pharmaceuticals, Inc. for educational talks.

William G. Wierda, MD, PhD
Professor, Department of Leukemia, Division of Cancer Medicine
D.B. Lane Cancer Research Distinguished Professor
Section Chief - Chronic Lymphocytic Leukemia
Center Medical Director
Executive Medical Director
The University of Texas MD Anderson Cancer Center
Houston, Texas

William G. Wierda, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Abbvie Inc.; Acerta Pharma, Inc.; Cyclacel Pharmaceuticals, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline/Novartis Pharmaceuticals Corporation; Janssen Pharmaceuticals, Inc.; Juno Therapeutics, Inc.; Kite Pharma; Loxo Oncology; miRagen Therapeutics, Inc.; Oncternal Therapeutics; Pharmacyclics LLC; Sunesis Pharmaceuticals, Inc.; and Xencor, Inc.

Medical Director
Carmine Deluca
PVI, PeerView Institute for Medical Education

Carmine Deluca has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit, and Support


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course #G6645-21-T.

Providership

This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.